{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-015846","form_type":"8-K","ticker":null,"cik":"0001817944","company_name":"Clarus Therapeutics Holdings, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.741614+00:00","generated_at":"2026-06-18T18:38:51.746717+00:00","sec_items":["1.03","2.01","3.03","5.01","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Clarus Therapeutics completes Chapter 11 liquidation; all common stock cancelled","bullets":["Plan effective Feb 28, 2023; all outstanding common stock cancelled and discharged.","Board of directors dissolved as of the Effective Date.","Company intends to file Form 15 to deregister securities and suspend SEC reporting.","Previously sold JATENZO assets to Tolmar in Oct 2022; sale approved by bankruptcy court.","Clarus will cease periodic reporting obligations upon Form 15 filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-015846","json":"https://secwatch.observer/filing/0001213900-23-015846.json","markdown":"https://secwatch.observer/filing/0001213900-23-015846.md","text":"https://secwatch.observer/filing/0001213900-23-015846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/0001213900-23-015846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/ea174454-8k_clarus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:38:51.746717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ec12b9733c0d03d82317a5da46b77a4a613906b","claim":"Clarus Therapeutics Holdings, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2022-09-05).","evidence_excerpt":"Clarus Therapeutics Holdings, Inc., or Clarus, and its wholly-owned subsidiary Clarus Therapeutics, Inc., or OpCo, filed voluntary petitions for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware, or the Court (Case No. 22-10845).","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/0001213900-23-015846-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the District of Delaware"},{"label":"Petition","value":"2022-09-05"}],"fact_type":"distress_event"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}